Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Elicio Therapeutics ( (ELTX) ) is now available.
On September 17, 2025, Elicio Therapeutics announced that its investigational vaccine, ELI-002 7P, achieved robust mKRAS-specific T cell responses in 99% of evaluable patients in the ongoing Phase 2 AMPLIFY-7P trial. The data showed significant improvements in T cell responses compared to previous Phase 1 trials, with an average increase of 145.3x over baseline. This consistency in response rates, including CD4 and CD8 T cells, suggests a promising outlook for the vaccine’s efficacy in treating mKRAS-driven cancers. The trial’s success could potentially expand the vaccine’s application to a broader patient population, enhancing Elicio’s market opportunities.
The most recent analyst rating on (ELTX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Elicio Therapeutics stock, see the ELTX Stock Forecast page.
Spark’s Take on ELTX Stock
According to Spark, TipRanks’ AI Analyst, ELTX is a Underperform.
Elicio Therapeutics faces significant financial challenges, with negative revenue growth and poor margins being the primary concerns. Technical analysis indicates bearish momentum, while the valuation aspect shows limited appeal. However, recent positive corporate events, such as leadership changes and clinical advancements, provide some optimism for future potential, albeit with high risk.
To see Spark’s full report on ELTX stock, click here.
More about Elicio Therapeutics
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. The company utilizes its proprietary AMP technology to enhance the activation and amplification of cancer-specific T cells, aiming to promote durable cancer immunosurveillance. Elicio’s lead product, ELI-002, targets common KRAS mutations, which are responsible for approximately 25% of all solid tumors.
Average Trading Volume: 82,381
Technical Sentiment Signal: Buy
Current Market Cap: $164.7M
See more insights into ELTX stock on TipRanks’ Stock Analysis page.